TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01876810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: 600 mg of gemfibrozil (one capsule) twice daily for two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One lactose pill twice a day for two weeks.
Study: NCT02531971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl citrate
Description: 100 micrograms (2 millilitres) via intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl citrate
Description: 100 micrograms (2 millilitres) via intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duragesic®
Description: TDDS dosage is 25 micrograms/hour (worn for 72 h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duragesic®
Description: TDDS dosage is 25 micrograms/hour (worn for 72 h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mylan generic fentanyl
Description: TDDS dosage is 25 micrograms/hour (worn for 72 h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mylan generic fentanyl
Description: TDDS dosage is 25 micrograms/hour (worn for 72 h)
Study: NCT01430754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20 mg tasimelteon capsules, daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, daily
Study: NCT01069185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Necessity endotracheal suctioning
Description: Endotracheal suctioning depends on clinical manifestations

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Routine endotracheal suctioning
Description: Endotracheal suctioning every two hours
Study: NCT01298544

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.
Study: NCT00356122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 70 mg/m\^2 administered intravenously (IV) on Day 1 for Cycles 1-6 (the treatment cycle is 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100 mg/m\^2 administered IV on Day 1 for Cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered IV on Day 1 for Cycles 1-6, and every 3 weeks during maintenance therapy for a total treatment of one year, until disease progression or death due to any cause, whichever occurs first.
Study: NCT00491556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Initiation of Highly Active Anti-Retroviral Therapy
Description: Treatment: TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r. Duration: Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Care
Description: Progression: Subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur. Treatment: HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care. Duration: three years.
Study: NCT01030783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib (AV-951)
Description: Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Study: NCT01495871

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acids
Description: 15 grams amino acids two times per day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of inert compounds
Description: Placebo two times per day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Valine
Description: 2.5 grams valine supplementation two times a day for 6 weeks
Study: NCT03620591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intraoperative administration of lidocaine
Study: NCT04017403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium triple live capsule
Description: Bifidobacterium triple live capsules, indications for acute and chronic diarrhea and constipation caused by intestinal flora imbalance, can also be used for the treatment of mild to moderate acute diarrhea, chronic diarrhea and indigestion, bloating, and adjuvant treatment of intestinal flora Endotoxemia caused by disorders.
Study: NCT01857154

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: All subjects in the study cohort will be administered 800 IU Vitamin D3.
Study: NCT03388944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCT group
Description: In this group antibiotic therapy will be stopped based on serial PCT measurements starting from admission.
Study: NCT01808742

Intervention type: DEVICE
Intervention: Treatment with CryoTouch III Device
Description: Bilateral forehead treatment with CryoTouch III device on the temporal branch of the facial nerve. Subject will be treated once and may be retreated up to 7 days after initial treatment.
Study: NCT03620591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intraoperative administration of normal saline
Study: NCT04017403

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos were administrated as same as the bifidobacterium live capsule
Study: NCT04297007

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PECS block
Description: A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid intercostal block
Description: A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study: NCT01961531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuboost APBI
Description: 28Gy delivered in 5 daily fractions
Study: NCT04097483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Intervention Group
Description: Nurse-led, telephone-based, and psychoeducational intervention centered on motivational interviewing and cognitive behavioral therapy for adherence and depression.
Study: NCT01633450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zinc biofortified rice
Description: 1.12 mg zinc per meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice extrinsically fortified with zinc
Description: 1.12 mg zinc per meal
Study: NCT05198947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin Lotion 5%
Description: Topical permethrin 5% lotion to apply on day 1 and repeat after 1 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin Lotion 5% and Oral Ivermectin 200 mcg/kg
Description: Topical permethrin 5% lotion and oral ivermectin 200 mcg/kg to be taken on day 1 only.
Study: NCT02288221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient's answer with non pharmacological therapeutic
Description: Installation at patient's home of :~* aromatherapy~* music therapy~* cognitive training in multimedia application offering cognitive games

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient's answer without non pharmacological therapeutic
Description: No installation at patient's home
Study: NCT02023229

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched-chain aminoacids

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-fiber high protein diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fiber high protein diet
Study: NCT04712045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New PPE
Description: The use of a new protocol of level 2 PPE which involves wearing a short-sleeve gown and a single pair of gloves

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Old PPE
Description: The use of a standard protocol of level 2 PPE which involves wearing a long-sleeve gown and double pairs of gloves
Study: NCT01162525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (pTNS)
Description: A 34 gauge needle in placed close to the tibial nerve about 2-3 cm above the ankle. A self-adhesive surface electrode is placed on the skin. Needle and surface electrode are connected to an electric stimulator and the stimulating current (0 - 10 mA) is increased in 20 steps. When the patient feels a tingling sensation in the foot, stimulating current is set back for one step and the treatment is started (30 min stimulation).
Study: NCT01241539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 150 mg capsule
Study: NCT00271752

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Earlier therapeutic changes regarding infection
Description: For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified
Study: NCT01241539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 75 mg capsule
Study: NCT00271752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Earlier therapeutic changes regarding infection
Description: For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified
Study: NCT01587404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL® SMARTTOUCH™ Catheter (including Surround Flow)
Description: Variable contact force as measured at the catheter tip within the left atrium
Study: NCT02296008

Intervention type: DEVICE
Group type: OTHER
Intervention: 3D high resolution anorectal manometry
Description: Procedure will take about 15 minutes. During procedure resting, squeeze, bear down maneuver, cough, ano-anal and rectoanal inhibitory reflex will be obtained, if possible.~3D picture of pressures of anorectal will be recorded.
Study: NCT01241539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 110 mg capsule
Study: NCT01606462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
Study: NCT03185130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline 5mL
Description: Control arm subjects will receive Normal Saline 5 mL IV over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline 20mL/kg
Description: Study arm subjects will receive Normal Saline 20 mL/kg IV (up to 1000 mL) given IV over 1 hour,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine 0.15 mg/kg up to 10 mg IV
Description: Standard Treatment Arm and Study Arm will receive prochlorperazine 0.15 mg/kg up to 10mg IV slow push

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 0.15 mg/kg up to 10 mg IV
Description: Standard Treatment Arm and Study Arm will receive prochlorperazine 0.15 mg/kg up to 10mg IV slow push

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine 1 mg/kg up to 50 mg IV
Description: Diphenhydramine dose 1 mg/kg up to 50 mg IV slow push
Study: NCT03948386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isobaric bupivacaine
Description: The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric bupivacaine
Description: TThe anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isobaric mepivacaine
Description: The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
Study: NCT03185130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 1 mg/kg up to 50 mg IV
Description: Diphenhydramine dose 1 mg/kg up to 50 mg IV slow push
Study: NCT02361346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724 Phase 1
Description: Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.
Study: NCT03979729

Intervention type: OTHER
Intervention: Routine Screening Mammogram (3D + 2D)
Description: Subjects that have undergone a routine screening mammogram (3D + 2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.

Intervention type: OTHER
Intervention: Routine Screening Mammogram (2D)
Description: Subjects that have undergone a routine screening mammogram (2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.

Intervention type: OTHER
Intervention: No Screening Mammogram
Description: Subjects will participate in a one-time facilitated focus group.
Study: NCT01071070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol
Description: Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol
Description: Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
Study: NCT03752905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTR-01
Description: Recombinant human collagen 7 (rC7)
Study: NCT02361346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724 Phase 1
Description: Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724 Phase 1
Description: Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724 Phase 1
Description: Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724 Phase 1
Description: Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724 Phase 1
Description: Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724 Phase 1
Description: Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.
Study: NCT02361346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724 Phase 2
Description: Intravenous dosing on Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 1 hour on each dosing day over 21 day cycle up to 6 cycles and then can be continued for 6 additional cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724 Phase 2
Description: Intravenous dosing on Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 1 hour on each dosing day over 21 day cycle up to 6 cycles and then can be continued for 6 additional cycles.
Study: NCT03752905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTR-01
Description: Recombinant human collagen 7 (rC7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTR-01
Description: Recombinant human collagen 7 (rC7)
Study: NCT02361346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724 Phase 2
Description: Intravenous dosing on Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 1 hour on each dosing day over 21 day cycle up to 6 cycles and then can be continued for 6 additional cycles.
Study: NCT02013141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Study: NCT00782795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Participants randomized to pioglitazone receive 30 mg taken once daily for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01015131

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FLT-PET/CT Imaging
Description: Participants receive the investigational radiotracer 18F-FLT intravenously and undergo Positron Emission Tomography (PET)/Computed Tomography (CT) scans at the following three times: prior to initiation of chemotherapy, at the end of the first cycle of treatment, and at the conclusion of chemotherapy.
Study: NCT04480424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAMUNEX-C
Description: Intravenous Immune Globulin (Human), 10% Caprylate/Chromatography Purified.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: SMT per local policies or guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: SMT per local policies or guidelines.
Study: NCT01857583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15mg DU-176b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15mg DU-176b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30mg DU-176b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux
Study: NCT02211638

Intervention type: DRUG
Intervention: Candesartan Cilexetil
Description: Candesartan Cilexetil tablet
Study: NCT02782923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STISIM driving simulator
Description: This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: STISIM driving simulator
Description: This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STISIM driving simulator
Description: This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STISIM driving simulator
Description: This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STISIM driving simulator
Description: This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STISIM driving simulator
Description: This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.
Study: NCT04382755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zilucoplan®
Description: 14 days of SC Zilucoplan® on top of standard of care + prophylactic antibiotics until 14 days after last Zilucoplan®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: standard of care treatment + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)